

## NEW CLAIM 23

<sup>16</sup>  
--23. The therapeutic agent of Claim <sup>14</sup>~~21~~ wherein the antibody is an scFv.--

## NEW CLAIM 24

F4  
--24. A therapeutic agent for the treatment of glomerulonephritis, wherein the therapeutic agent is sterile and non-pyrogenic and comprises the antibody of Claim 1 and a pharmaceutically effective carrier.--

## NEW CLAIM 25

sm 62  
--25. The therapeutic agent of Claim 24 wherein the antibody is a humanized antibody.--

**Remarks**

This is supplemental to the supplemental amendment of November 4, 1998 and the response, mailed August 14, 1998, to the Office Action dated February 18, 1998 in the above referenced application. No extension of time is believed to be required for this paper, but should any such extension be required the Commissioner is requested to consider this a petition therefor. The Commissioner is hereby authorized to charge any fees that may be required by this paper to Deposit Account No. 01-0483.


Claims 1-12 are pending in the present application. New dependent Claims 18-25 are being added as set forth above in order to claim certain functional attributes of the antibodies of the invention. Support for these new claims can be found throughout applicants' specification. For example: support for claim 18 can be found at page 27, lines 22-24 and page 31, lines 21-23; support for claim 19 can be found at page 27, lines 28-30; support for claims 20 and 21 can be found at page 11, lines 1-4 and at page 31, lines 26-30; support for claims 22-23 can be found at page 35, lines 4-13, with additional support being found on page 10, lines 21 to 23 and claims 7 and 8 as filed; support for claim 24-5 can be found at page 11, lines 1-7 and at page 31, lines 26-30.

When this amendment is entered, there will be one independent claim and 20 total claims pending in this application.

**Conclusion**

Applicants respectfully request entry of the above amendments, reconsideration and allowance of claims 1-12 and consideration and allowance of new claims 18-25.

Respectfully submitted,



Seth A. Fidel, Ph.D.  
Reg. No. 38,449  
Agent for Applicants  
Alexion Pharmaceuticals  
25 Science Park, Suite 360  
New Haven, CT 06511  
(203) 776-1790

Date: January 11, 1999